E7208: A Randomized Phase II Study of Irinotecan and Cetuximab with or without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy (ECOG 7208)
What is the purpose of this trial?
- Eastern Cooperative Oncology Group
- Last Updated:
- Study HIC#: